Navigation Links
Could Estriol Be Used as a Therapy for Treating MS?

It has long been common knowledge that pregnant women with multiple sclerosis (MS) experience a sharp drop in the disease’s symptoms during// the course of their pregnancy.

Some years back, Dr. Rhonda Voskuhl, director of UCLA’s Multiple Sclerosis Program, and her colleagues discovered the cause. They found that a female sex hormone called estriol, which is produced during pregnancy, was responsible for the suppression. Four years ago, Voskuhl followed that discovery with a pilot study in which 10 non-pregnant women with MS were given estriol, yielding what she described as “pretty remarkable” results — an 80 percent drop in inflammatory lesions in the brain, a hallmark of the disease.

This month, Voskuhl begins a much larger trial of estriol, one that will involve 150 patients at multiple locations over the next two years. The prospects, she said, are exciting.

Multiple sclerosis is an autoimmune disease of the central nervous system that attacks the tissue surrounding the brain’s nerve fibers. This tissue, called myelin, can be thought of as the insulation wrapped around an electrical wire. When the myelin is damaged, the nerve’s ability to send signals to and from the brain is interfered with, resulting in symptoms common to MS, including problems with balance, memory, vision loss and more.

Currently, anti-inflammatory drugs used to treat MS lessen the symptoms and slow the progression of the disease. But they must be given by injection daily, weekly or monthly — depending on the drug — and are expensive, costing between $12,000 to $24,000 a year.

Estriol is a hormone produced by the placenta that is virtually undetectable until pregnancy, when it progressively increases. It is thought that its role is to suppress a woman’s immune system when she is pregnant, so that the fetus will not be seen by the body as a foreign “invader.”

“The beauty of estriol is that it can be given as a pill, no
'"/>




Page: 1 2

Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Nasal Spray Could Take Drugs Direct to Brain.
3. Nasal Spray Could Take Drugs Directly to Brain
4. Oxygen Usage During Exercise Could Indicate Heart Problems
5. Ultrasound Screening Could Improve The Outcome Of Critically ill Patients
6. Anger Could Be Linked To Weight Gain
7. A Seizure Late In Life Could be A Stroke Warning
8. New Findings Could Reduce The Extent Of Spinal Cord Injuries
9. Could There Be A Link Between Famine and Breast Cancer ?
10. Bone Marrow Cells Could Yield A New Lease of Life
11. New Hair in 15 Days Could Now Be A Possibility Say Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Could Estriol Used Therapy for Treating

Breaking Medicine Technology:Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5FDA Launches Orphan Drug Workshop at KGI 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Companion Life Adds Dental Tourism Option to Help Policyholders Save 60761 1Companion Life Adds Dental Tourism Option to Help Policyholders Save 60761 2Companion Life Adds Dental Tourism Option to Help Policyholders Save 60761 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 1SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 14SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 14733 1SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 14733 2